港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

翰思艾泰-B

17.390

+0.1901.10%

成交量：116.26萬

成交額：2,067.51萬

市值：23.69億

市盈率：- -

高：18.500

開：17.200

低：17.200

收：17.200

52周最高：29.480

52周最低：17.200

股本：1.36億

香港流通股本：1.36億

量比：0.26

換手率：0.85%

股息：- -

股息率：- -

淨資產收益率：-43.61%

總資產收益率：-13.64%

市淨率：12.84

市盈率(LYR):- -

市銷率: 970.90

資料載入中...

總覽公司新聞資訊公告

翰思艾泰港交所上市首日大跌30%！5.9億港元孖展押注腫瘤免疫與ADC創新藥，HX009領銜多管線佈局

市值近44億港元，光谷又誕生一家上市公司

冰與火之歌：寶濟藥業(02589)180%暴漲vs華芢生物(02396)、翰思艾泰(03378)腰斬港股生物科技新股極端分化啓示錄

智通财经网

異動解讀 | 翰思艾泰-B盤中大漲5.23%，創新藥HX111獲批臨牀試驗提振股價

諾比侃、輕鬆健康、翰思艾泰正式登陸港交所；海致科技、龍迅股份、濰柴雷沃遞表港交所丨港交所早參

每日经济新闻

翰思艾泰-B(03378)獲批准於中華人民共和國開展注射用HX111臨牀試驗

3000倍超購換來首日暴跌近50%，翰思艾泰-B(03378)何以成為抽新股「陷阱」？

光谷，又一家生物企業敲鐘上市！

【IPO追蹤】創新藥新股再遭破發！被「哄搶」的翰思艾泰遭大跌

農銀國際作為聯席全球協調人協助翰思艾泰成功在香港聯交所上市

武漢又衝出一個醫藥IPO！60歲武大學霸帶隊

翰思艾泰正式登陸港交所，市值39億港元，核心產品HX009正在中國進行三個臨牀項目

独角兽早知道

港股不行了？今天這家新藥上市又是大跌30%

翰思艾泰港交所上市破發跌9%，總市值39.6億港元

異動解讀 | 翰思艾泰-B首日盤中大跌9.56%，高風險管線與財務隱憂引發拋售

新股首日 | 翰思艾泰-B(03378)首掛上市早盤低開9.69% 核心產品HX009正在中國進行三個臨牀項目

翰思艾泰-B股票將在香港首次公開交易時以每股28.9港元開盤，較發行價32港元有所下跌

三隻新股同日暗盤！最高大漲超275%，一手賺超1.1萬港元

港股IPO動態：今日翰思艾泰、輕鬆健康、諾比侃上市，壁仞科技等7股申購

翰思艾泰生物(3378)香港公開發售超額認購3074倍基石投資者認購15.93% 擬於12月...

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/stock/03378/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03378","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","market":"HK","secType":"STK","nameCN":"翰思艾泰-B","latestPrice":17.39,"timestamp":1766549302745,"preClose":17.2,"halted":0,"volume":1162600,"delay":0,"floatShares":136218830,"shares":136218830,"eps":0,"marketStatus":"聖誕節休市","change":0.19,"latestTime":"12-24 12:08:22","open":17.2,"high":18.5,"low":17.2,"amount":20675055,"amplitude":0.075581,"askPrice":17.39,"askSize":400,"bidPrice":17.3,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1766419200000,"exchange":"SEHK","adjPreClose":17.2,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":0.2582746816687275,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"000905","market":"SZ","secType":"STK","nameCN":"廈門港務","latestPrice":14.17,"timestamp":1766646000000,"preClose":14.2,"halted":0,"volume":92754100,"delay":0,"premium":"+10.61"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03378\",,,,,undefined,":{"symbol":"03378","floatShares":136218830,"roa":"-13.64%","roe":"-43.61%","lyrEps":0,"volumeRatio":0.2582746816687275,"shares":136218830,"dividePrice":0,"high":18.5,"amplitude":0.075581,"preClose":17.2,"low":17.2,"week52Low":17.2,"pbRate":"12.84","psRate":"970.90","week52High":29.48,"institutionHeld":0,"latestPrice":17.39,"committee":0.428571,"eps":0,"divideRate":0,"volume":1162600,"delay":0,"ttmEps":0,"open":17.2,"prevYearClose":32,"prevWeekClose":32,"prevMonthClose":32,"prevQuarterClose":32,"fiveDayClose":32,"twentyDayClose":32,"sixtyDayClose":32},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03378\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03378\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03378\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/03378\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"03378","date":"2025-12-24","current":-18.447668,"percent":0,"low":-18.447668,"twenty":4.982674,"median":6.211114,"eighty":10.220738,"high":11.401072,"avg":7.071291,"sd":2.992137,"marketCap":2368845453},"quantilePoints":[{"date":"2020-12-31","current":9.307742,"twenty":6.241855,"median":8.793266,"eighty":10.503662,"marketCap":3107868000},{"date":"2021-01-08","current":9.233986,"twenty":6.241825,"median":8.78901,"eighty":10.48563,"marketCap":3107868000},{"date":"2021-01-15","current":10.453273,"twenty":6.241825,"median":8.78901,"eighty":10.488698,"marketCap":3516798000},{"date":"2021-01-22","current":9.647002,"twenty":6.241825,"median":8.792168,"eighty":10.488698,"marketCap":3244178000},{"date":"2021-01-29","current":9.728706,"twenty":6.241825,"median":8.812261,"eighty":10.488698,"marketCap":3298702000},{"date":"2021-02-05","current":9.706444,"twenty":6.24107,"median":8.821195,"eighty":10.49321,"marketCap":3271440000},{"date":"2021-02-11","current":10.50026,"twenty":6.241817,"median":8.835985,"eighty":10.49615,"marketCap":3544060000},{"date":"2021-02-19","current":11.141569,"twenty":6.241319,"median":8.855578,"eighty":10.52353,"marketCap":3762156000},{"date":"2021-02-26","current":10.195145,"twenty":6.241319,"median":8.865139,"eighty":10.536788,"marketCap":3435012000},{"date":"2021-03-05","current":10.950823,"twenty":6.24107,"median":8.870518,"eighty":10.569441,"marketCap":3680370000},{"date":"2021-03-12","current":10.482471,"twenty":6.24107,"median":8.877847,"eighty":10.591134,"marketCap":3516798000},{"date":"2021-03-19","current":10.648533,"twenty":6.240821,"median":8.876278,"eighty":10.604656,"marketCap":3571322000},{"date":"2021-03-26","current":10.124223,"twenty":6.24107,"median":8.877847,"eighty":10.605193,"marketCap":3380488000},{"date":"2021-04-01","current":8.974412,"twenty":6.241319,"median":8.879416,"eighty":10.605108,"marketCap":3026082000},{"date":"2021-04-09","current":9.115992,"twenty":6.240821,"median":8.876278,"eighty":10.605277,"marketCap":3080606000},{"date":"2021-04-16","current":9.081606,"twenty":6.240821,"median":8.876278,"eighty":10.605277,"marketCap":3080606000},{"date":"2021-04-23","current":8.898598,"twenty":6.240821,"median":8.870388,"eighty":10.605277,"marketCap":3026082000},{"date":"2021-04-30","current":7.616306,"twenty":6.240821,"median":8.865139,"eighty":10.605277,"marketCap":2998820000},{"date":"2021-05-07","current":8.408393,"twenty":6.240821,"median":8.865139,"eighty":10.605277,"marketCap":2889772000},{"date":"2021-05-14","current":8.572623,"twenty":6.240572,"median":8.870518,"eighty":10.605361,"marketCap":2944296000},{"date":"2021-05-21","current":9.125741,"twenty":6.240515,"median":8.879786,"eighty":10.605492,"marketCap":3135130000},{"date":"2021-05-28","current":7.973288,"twenty":6.240515,"median":8.880182,"eighty":10.605492,"marketCap":3189654000},{"date":"2021-06-04","current":8.148212,"twenty":6.240457,"median":8.880655,"eighty":10.605622,"marketCap":3244178000},{"date":"2021-06-10","current":8.073784,"twenty":6.240515,"median":8.880182,"eighty":10.605492,"marketCap":3216916000},{"date":"2021-06-18","current":7.248909,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2862510000},{"date":"2021-06-25","current":6.977152,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2753462000},{"date":"2021-06-30","current":6.560321,"twenty":6.2404,"median":8.881129,"eighty":10.605753,"marketCap":2589890000},{"date":"2021-07-09","current":6.71929,"twenty":6.240342,"median":8.881945,"eighty":10.605883,"marketCap":2644414000},{"date":"2021-07-16","current":6.511612,"twenty":6.240342,"median":8.881945,"eighty":10.605883,"marketCap":2562628000},{"date":"2021-07-23","current":6.096563,"twenty":6.238278,"median":8.881945,"eighty":10.605883,"marketCap":2399056000},{"date":"2021-07-30","current":5.79996,"twenty":6.233026,"median":8.881945,"eighty":10.605883,"marketCap":2290008000},{"date":"2021-08-06","current":6.090856,"twenty":6.221418,"median":8.881945,"eighty":10.605883,"marketCap":2399056000},{"date":"2021-08-13","current":6.220809,"twenty":6.220848,"median":8.881945,"eighty":10.605883,"marketCap":2453580000},{"date":"2021-08-20","current":5.891906,"twenty":6.215651,"median":8.881129,"eighty":10.606014,"marketCap":2317270000},{"date":"2021-08-27","current":6.211114,"twenty":6.21107,"median":8.882761,"eighty":10.607478,"marketCap":2453580000},{"date":"2021-09-03","current":5.545615,"twenty":6.208353,"median":8.884377,"eighty":10.608943,"marketCap":2453580000},{"date":"2021-09-10","current":5.900149,"twenty":6.193519,"median":8.880182,"eighty":10.608943,"marketCap":2617152000},{"date":"2021-09-17","current":5.547797,"twenty":6.178602,"median":8.879984,"eighty":10.608211,"marketCap":2453580000},{"date":"2021-09-24","current":5.395896,"twenty":6.168457,"median":8.870647,"eighty":10.603497,"marketCap":2371794000},{"date":"2021-09-30","current":5.316083,"twenty":6.15787,"median":8.864959,"eighty":10.580915,"marketCap":2344532000},{"date":"2021-10-08","current":5.316326,"twenty":6.147257,"median":8.853246,"eighty":10.544157,"marketCap":2344532000},{"date":"2021-10-15","current":5.374457,"twenty":6.140429,"median":8.815924,"eighty":10.511884,"marketCap":2371794000},{"date":"2021-10-22","current":5.27481,"twenty":6.127225,"median":8.797247,"eighty":10.493516,"marketCap":2344532000},{"date":"2021-10-29","current":5.349373,"twenty":6.119344,"median":8.779365,"eighty":10.475509,"marketCap":2371794000},{"date":"2021-11-05","current":4.889355,"twenty":6.114079,"median":8.748721,"eighty":10.420921,"marketCap":2208222000},{"date":"2021-11-12","current":4.809165,"twenty":6.108215,"median":8.717377,"eighty":10.3914,"marketCap":2180960000},{"date":"2021-11-19","current":4.876179,"twenty":6.101111,"median":8.695621,"eighty":10.35108,"marketCap":2208222000},{"date":"2021-11-26","current":4.87462,"twenty":6.084623,"median":8.671197,"eighty":10.318496,"marketCap":2208222000},{"date":"2021-12-03","current":5.22604,"twenty":6.078106,"median":8.624866,"eighty":10.2832,"marketCap":2371794000},{"date":"2021-12-10","current":5.037231,"twenty":6.070936,"median":8.60024,"eighty":10.227378,"marketCap":2290008000},{"date":"2021-12-17","current":4.86069,"twenty":6.054857,"median":8.564239,"eighty":10.190552,"marketCap":2208222000},{"date":"2021-12-24","current":4.916003,"twenty":6.052379,"median":8.514295,"eighty":10.154612,"marketCap":2235484000},{"date":"2021-12-31","current":5.144618,"twenty":6.047568,"median":8.504328,"eighty":10.145926,"marketCap":2344532000},{"date":"2022-01-07","current":5.164225,"twenty":6.042847,"median":8.4784,"eighty":10.143723,"marketCap":2344532000},{"date":"2022-01-14","current":5.093083,"twenty":6.038396,"median":8.458041,"eighty":10.124223,"marketCap":2317270000},{"date":"2022-01-21","current":5.380359,"twenty":6.023881,"median":8.434699,"eighty":10.073347,"marketCap":2453580000},{"date":"2022-01-28","current":5.034519,"twenty":6.017531,"median":8.407204,"eighty":10.033216,"marketCap":2290008000},{"date":"2022-02-04","current":5.156916,"twenty":6.014762,"median":8.39643,"eighty":10.012135,"marketCap":2344532000},{"date":"2022-02-11","current":5.206364,"twenty":6.007032,"median":8.358349,"eighty":9.99186,"marketCap":2371794000},{"date":"2022-02-18","current":5.240469,"twenty":5.997462,"median":8.310368,"eighty":9.985006,"marketCap":2399056000},{"date":"2022-02-25","current":4.989965,"twenty":5.989585,"median":8.200753,"eighty":9.95781,"marketCap":2290008000},{"date":"2022-03-04","current":4.928672,"twenty":5.979555,"median":8.170117,"eighty":9.938791,"marketCap":2262746000},{"date":"2022-03-11","current":4.876653,"twenty":5.973297,"median":8.123652,"eighty":9.894296,"marketCap":2235484000},{"date":"2022-03-18","current":4.717047,"twenty":5.960037,"median":8.070293,"eighty":9.868408,"marketCap":2153698000},{"date":"2022-03-25","current":5.194505,"twenty":5.957174,"median":8.005027,"eighty":9.829511,"marketCap":2371794000},{"date":"2022-04-01","current":4.531371,"twenty":5.948529,"median":7.973288,"eighty":9.81982,"marketCap":2317270000},{"date":"2022-04-08","current":4.649157,"twenty":5.946479,"median":7.953215,"eighty":9.804315,"marketCap":2371794000},{"date":"2022-04-14","current":4.707815,"twenty":5.940486,"median":7.879016,"eighty":9.79455,"marketCap":2399056000},{"date":"2022-04-22","current":4.802247,"twenty":5.934888,"median":7.843904,"eighty":9.78108,"marketCap":2399056000},{"date":"2022-04-29","current":4.825339,"twenty":5.919008,"median":7.698315,"eighty":9.768722,"marketCap":2371794000},{"date":"2022-05-06","current":4.410489,"twenty":5.9041,"median":7.676819,"eighty":9.755607,"marketCap":2399056000},{"date":"2022-05-13","current":4.541874,"twenty":5.900202,"median":7.615768,"eighty":9.747897,"marketCap":2426318000},{"date":"2022-05-20","current":6.290771,"twenty":5.897549,"median":7.514446,"eighty":9.724288,"marketCap":3407750000},{"date":"2022-05-27","current":7.303631,"twenty":5.895161,"median":7.434402,"eighty":9.709875,"marketCap":3952990000},{"date":"2022-06-02","current":7.264641,"twenty":5.89518,"median":7.334535,"eighty":9.703749,"marketCap":3952990000},{"date":"2022-06-10","current":10.869875,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5888592000},{"date":"2022-06-17","current":10.755528,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5806806000},{"date":"2022-06-24","current":10.662581,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5779544000},{"date":"2022-06-30","current":10.731352,"twenty":5.895161,"median":7.322855,"eighty":9.700394,"marketCap":5806806000},{"date":"2022-07-08","current":10.820976,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5861330000},{"date":"2022-07-15","current":10.871399,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5834068000},{"date":"2022-07-22","current":10.864271,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5834068000},{"date":"2022-07-29","current":11.058353,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5943116000},{"date":"2022-08-05","current":11.082085,"twenty":5.895141,"median":7.321962,"eighty":9.698882,"marketCap":5943116000},{"date":"2022-08-29","current":10.115403,"twenty":5.888507,"median":7.263276,"eighty":9.659414,"marketCap":6079426000},{"date":"2022-09-23","current":10.460916,"twenty":5.875785,"median":7.121577,"eighty":9.631568,"marketCap":6106688000},{"date":"2022-09-27","current":10.715865,"twenty":5.875785,"median":7.121577,"eighty":9.635273,"marketCap":6106688000},{"date":"2025-12-24","current":-18.447668,"twenty":4.982674,"median":6.211114,"eighty":10.220738,"marketCap":2368845453}],"updateTime":1766632483935},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03378\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2594284633","title":"翰思艾泰港交所上市首日大跌30%！5.9億港元孖展押注腫瘤免疫與ADC創新藥，HX009領銜多管線佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2594284633","media":"摩熵医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594284633?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 12:00","pubTimestamp":1766635251,"startTime":"0","endTime":"0","summary":"图源：摩熵医药数据库-全球药物研发数据库公司的定位是提供新一代肿瘤免疫治疗，如HX009、HX044及HX016，以对抗PD-1抗性；提供一流的ADC分子HX111，以精确治疗特定恶性肿瘤；以及提供新型自身免疫治疗，如BsAb双功能抗体HX035及HX038。2023年、2024年和2025年前八个月，翰思艾泰研发开支分别为人民币4,666.3万、7,472.1万和5,617.8万元；净亏损分别为人民币0.85亿、1.17亿和0.88亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225120125a475e3b9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","03378","BK1161","BK1535","06978","BK1173"],"gpt_icon":1},{"id":"2593477604","title":"市值近44億港元，光谷又誕生一家上市公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477604","media":"长江日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477604?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 19:53","pubTimestamp":1766577186,"startTime":"0","endTime":"0","summary":"12月23日，翰思艾泰生物医药科技（武汉）股份有限公司在港交所成功上市，成为光谷第71家上市公司。本次IPO，翰思艾泰全球发售1832.1万股，发行价为32港元每股，募资总额5.86亿港元，发行市值近44亿港元。截至目前，光谷境内外上市公司总数达71家，上市公司数量超过全市60%，约占全省1/3。在生命健康领域，光谷已有9家上市公司。目前光谷有6家公司进入上市审核程序，19家公司启动IPO辅导，2025年入库金种子公司209家，上市后备梯队持续扩充。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224212935a6ca9711&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224212935a6ca9711&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03378","BK1535","BK1173"],"gpt_icon":1},{"id":"2593942679","title":"冰與火之歌：寶濟藥業(02589)180%暴漲vs華芢生物(02396)、翰思艾泰(03378)腰斬 港股生物科技新股極端分化啓示錄","url":"https://stock-news.laohu8.com/highlight/detail?id=2593942679","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593942679?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 12:47","pubTimestamp":1766551655,"startTime":"0","endTime":"0","summary":"2025年12月，港股IPO市场上演了一场令人瞠目结舌的“冰与火之歌”。","market":"hk","thumbnail":"https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20251224/20251224125033_33927.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385346.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","02396","BK1233","BK1173","159837","03378","BK1587","BK1535","BK1616","02589"],"gpt_icon":1},{"id":"1148803609","title":"異動解讀 | 翰思艾泰-B盤中大漲5.23%，創新藥HX111獲批臨牀試驗提振股價","url":"https://stock-news.laohu8.com/highlight/detail?id=1148803609","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148803609?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 09:36","pubTimestamp":1766540183,"startTime":"0","endTime":"0","summary":"翰思艾泰-B今日盘中大涨5.23%，引起了市场的广泛关注。消息面上，公司开发的创新药注射用HX111已获中国国家药品监督管理局批准开展临床试验。HX111为首创OX40靶向抗体偶联药物，临床前研究显示，OX40在若干恶性肿瘤中相较于正常组织呈过度表达，成为ADC的合适靶点。翰思艾泰-B是一家专注于新一代免疫疗法开发的生物科技公司，此前已通过港股18A规则上市。HX111是公司继HX009及HX044两项双特异性抗体疗法后，推进至临床开发的第三个首创分子。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03378"],"gpt_icon":0},{"id":"2593414913","title":"諾比侃、輕鬆健康、翰思艾泰正式登陸港交所；海致科技、龍迅股份、濰柴雷沃遞表港交所丨港交所早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2593414913","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593414913?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 00:56","pubTimestamp":1766508987,"startTime":"0","endTime":"0","summary":"｜2025年12月24日星期三｜NO.1诺比侃、轻松健康、翰思艾泰正式登陆港交所12月23日，诺比侃（HK02635）、轻松健康（HK02661）、翰思艾泰-B（HK03378）正式登陆港交所。上市首日，诺比侃、轻松健康高开高走，翰思艾泰低开低走。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512243599889373.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243599889373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0231","BK0214","03378","BK1535","02661","02635","BK1173","688486"],"gpt_icon":1},{"id":"2593418386","title":"翰思艾泰-B(03378)獲批准於中華人民共和國開展注射用HX111臨牀試驗","url":"https://stock-news.laohu8.com/highlight/detail?id=2593418386","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593418386?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 21:12","pubTimestamp":1766495577,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，由本公司开发的创新药注射用HX111已获中华人民共和国国家药品监督管理局批准于中华人民共和国境内开展临床试验。HX111为首创OX40靶向抗体偶联药物。临床前研究表明，OX40为肿瘤相关抗原，于若干恶性肿瘤中相较于正常组织呈过度表达，因而成为如HX111等ADC方式的合适靶点。HX111为本公司继HX009及HX044两项FIC双特异性抗体疗法后，推进至临床开发的第三个首创分子。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385147.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","03378","BK1535"],"gpt_icon":1},{"id":"2593492943","title":"3000倍超購換來首日暴跌近50%，翰思艾泰-B(03378)何以成為抽新股「陷阱」？","url":"https://stock-news.laohu8.com/highlight/detail?id=2593492943","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593492943?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 19:46","pubTimestamp":1766490417,"startTime":"0","endTime":"0","summary":"继12月22日华生物-B首挂当日股价收跌近30%后，12月23日首挂上市的翰思艾泰-B同样受到市场“暴击”。根据发行计划，此次翰思艾泰全球发售1832.1万股H股。从财务表现来看，2023年、2024年及2025年前8个月，翰思艾泰期内亏损分别为8516.0万元、1.17亿元、8743.8万元。截至2025年10月31日，现金及其等价物为1.33亿元，流动负债总额为2.2亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1173","03378","BK1535"],"gpt_icon":1},{"id":"2593491216","title":"光谷，又一家生物企業敲鐘上市！","url":"https://stock-news.laohu8.com/highlight/detail?id=2593491216","media":"IVD资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593491216?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 17:43","pubTimestamp":1766482984,"startTime":"0","endTime":"0","summary":"来源：中国光谷12月23日，翰思艾泰生物医药科技（武汉）股份有限公司在港交所成功上市，成为光谷第71家上市公司。翰思艾泰上市敲钟现场翰思艾泰成立于2014年，专注研发用于癌症及自身免疫疾病精准治疗的创新药。截至目前，公司拥有10款候选药物管线，其中3款处于临床阶段、7款处于临床前阶段。翰思艾泰生物成立于2014年，是一家专注于结构生物学、转化医学及临床开发的创新型生物科技公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223185350a46e9c49&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223185350a46e9c49&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1535","03378"],"gpt_icon":1},{"id":"2593673764","title":"【IPO追蹤】創新藥新股再遭破發！被「哄搶」的翰思艾泰遭大跌","url":"https://stock-news.laohu8.com/highlight/detail?id=2593673764","media":"IPO解码","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593673764?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 15:19","pubTimestamp":1766474346,"startTime":"0","endTime":"0","summary":"值得注意的是，在招股阶段，翰思艾泰获得了投资者的热情申购。根据资料，香港公开发售方面，翰思艾泰获3074.09倍认购，公开发售股份最终数目为183.21万股股份，占发售股份总数的约10%。截至2025年12月8日，翰思艾泰已在澳大利亚及中国完成HX009的I期临床试验。作者丨燕十四编辑丨Danna●中学教师携传感器闯港股，奥迪威竞争压力凸显●四只新股齐破发！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223153329a6c4d98d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223153329a6c4d98d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1535","BK1173","BK1574","06978","03378"],"gpt_icon":1},{"id":"2593422465","title":"農銀國際作為聯席全球協調人協助翰思艾泰成功在香港聯交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593422465","media":"农银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593422465?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 11:33","pubTimestamp":1766460805,"startTime":"0","endTime":"0","summary":"2025年12月23日，农银国际作为联席全球协调人、联席账簿管理人及联席牵头经办人协助翰思艾泰生物医药科技(武汉)股份有限公司在香港交易所主板成功上市。农银国际作为联席全球协调人、联席账簿管理人及联席牵头经办人，凭借自身对生物医药行业及跨境资本的深度理解，积极沟通高质量投资人，为公司成功上市保驾护航。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223114202a6c41941&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223114202a6c41941&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","BK1535","03378"],"gpt_icon":1},{"id":"2593639194","title":"武漢又衝出一個醫藥IPO！60歲武大學霸帶隊","url":"https://stock-news.laohu8.com/highlight/detail?id=2593639194","media":"创业邦","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593639194?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 11:23","pubTimestamp":1766460221,"startTime":"0","endTime":"0","summary":"翰思艾泰正在研发用于癌症及自身免疫疾病精准治疗的创新药，解决该领域未被满足的医疗需求。01湖北农村走出的IPO敲钟人现年60岁的张发明，出生在湖北天门石家河镇的一个普通农村家庭，16岁时考入武汉大学物理化学专业，是家中第一个走出乡村的大学生。以此为平台，张发明正式进军创新药研发。HX009是一款PD-1/SIRPα双功能抗体融合蛋白，其设计旨在同时阻断PD-1免疫抑制信号和CD47-SIRPα介导的免疫逃逸信号，从而协同激活T细胞和巨噬细胞，对抗肿瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223112437a6c409fc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","09939","03378","BK1515","BK1535","BK1173","BK1574"],"gpt_icon":1},{"id":"2593746868","title":"翰思艾泰正式登陸港交所，市值39億港元，核心產品HX009正在中國進行三個臨牀項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593746868","media":"独角兽早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593746868?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 10:57","pubTimestamp":1766458668,"startTime":"0","endTime":"0","summary":"今日开盘，翰思艾泰报28.90港元/股，市值39.37亿港元。公司已在澳大利亚及中国完成HX009的I期临床试验。翰思艾泰亦有两款主要产品，两款产品处于临床阶段，专注于治疗癌症。公司已完成根据国家药监局批准对HX301进行的I期临床研究，且目前正在中国开展HX301与替莫唑胺联用治疗脑胶质母细胞瘤的II期临床研究。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223105947a6c3f281&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"5d00d451d0b030a5ac6d3e3b899c155a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223105947a6c3f281&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","03378","BK1173"],"gpt_icon":1},{"id":"2593946824","title":"港股不行了？今天這家新藥上市又是大跌30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593946824","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593946824?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 10:47","pubTimestamp":1766458020,"startTime":"0","endTime":"0","summary":"2025年12月23日，湖北武汉的翰思艾泰生物科技(武汉)股份有限公司在港交所上市，大跌30%。本次发行1832.1万股，发行价32港元/股，规模约5.9亿港元（约合7500万美元）。公司有核心产品HX009（PD-1/SIRPα双功能抗体融合蛋白）、两款主要产品HX044及HX301，还有7项临床前阶段候选药物。其定位是提供新一代肿瘤免疫治疗、一流ADC分子及新型自身免疫治疗。2023年、2024年和2025年前八个月，公司研发开支分别为4666.3万、7472.1万和5617.8万元，净亏损分别为0.85亿、1.17亿和0.88亿元。文中未提及投资机构、财务顾问及融资目的。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223110617a46cf17e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2593452767","title":"翰思艾泰港交所上市破發跌9%，總市值39.6億港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593452767","media":"瑞财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593452767?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:34","pubTimestamp":1766453667,"startTime":"0","endTime":"0","summary":"12月23日，翰思艾泰-B（03378.HK）在港交所挂牌上市，独家保荐人为工银国际，开盘跌9.25%，总市值39.56亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223093442a46c8f30&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223093442a46c8f30&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":0},{"id":"1116178869","title":"異動解讀 | 翰思艾泰-B首日盤中大跌9.56%，高風險管線與財務隱憂引發拋售","url":"https://stock-news.laohu8.com/highlight/detail?id=1116178869","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1116178869?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:32","pubTimestamp":1766453552,"startTime":"0","endTime":"0","summary":"翰思艾泰-B今日首日挂牌交易，盘中股价一度大跌9.56%，开盘报28.9港元，较发行价32港元低开9.69%。消息面上，翰思艾泰的核心产品HX009是全球唯一靶向PD-1与CD47的双抗药物，但CD47靶点因严重血液毒性风险被国际药企普遍放弃，其管线尚未跨过临床II期\"死亡谷\"，商业化前景存疑。公司近年净亏损持续扩大，2025年前8个月亏损同比增超80%，且存在对赌协议压力，若2026年底前未达里程碑或触发大额赎回。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5d00d451d0b030a5ac6d3e3b899c155a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["03378"],"gpt_icon":0},{"id":"2593268452","title":"新股首日 | 翰思艾泰-B(03378)首掛上市 早盤低開9.69% 核心產品HX009正在中國進行三個臨牀項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2593268452","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593268452?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:25","pubTimestamp":1766453142,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，翰思艾泰-B首挂上市，公告显示，每股定价32港元，共发行1832.1万股股份，每手100股，所得款项净额约5.31亿港元。截至发稿，跌9.69%，报28.9港元，成交额7566.97万港元。公开资料显示，翰思艾泰的核心产品HX009是一种同时靶向CD47及PD-1的双特异性抗体融合蛋白。根据弗若斯特沙利文报告，截至最后实际可行日期，HX009的临床试验进展在同类CD47靶向双特异性抗体/双功能融合蛋白产品中处于全球领先地位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384723.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03378","BK1535","BK1173"],"gpt_icon":1},{"id":"1140374296","title":"翰思艾泰-B股票將在香港首次公開交易時以每股28.9港元開盤，較發行價32港元有所下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1140374296","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1140374296?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 09:24","pubTimestamp":1766453097,"startTime":"0","endTime":"0","summary":"翰思艾泰-B股票将在香港首次公开交易时以每股28.9港元开盘，较发行价32港元有所下跌。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"5d00d451d0b030a5ac6d3e3b899c155a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1535","BK1173","03378"],"gpt_icon":0},{"id":"2593459806","title":"三隻新股同日暗盤！最高大漲超275%，一手賺超1.1萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459806","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593459806?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 07:29","pubTimestamp":1766446140,"startTime":"0","endTime":"0","summary":"　　12月22日，港股三只新股暗盘同时开启，行情走势却呈现冰火两重天。　　整体而言，三只新股的表现差异与其所处赛道的近期行情关系密切。其中，专注于人工智能产业化应用的诺比侃，暗盘股价大涨275.75%；提供数字综合健康服务及健康保险解决方案的轻松健康，暗盘亦大涨127.95%；但创新药赛道的翰思艾泰-B却表现平平，暗盘最终仅录得2.06%的涨幅。　　富途暗盘数据显示，诺比侃暗盘收涨275.75%，报300.60港元/股，每手50股，不计手续费，一手赚11030港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-12-23/doc-inhctsyw1032451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","BK4543","BK4551","02635","BK1535","BK4023","BK1173","BK4588","02661","BK4528","BK4587","03378","AI"],"gpt_icon":1},{"id":"2593945584","title":"港股IPO動態：今日翰思艾泰、輕鬆健康、諾比侃上市，壁仞科技等7股申購","url":"https://stock-news.laohu8.com/highlight/detail?id=2593945584","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593945584?lang=zh_tw&edition=fundamental","pubTime":"2025-12-23 06:14","pubTimestamp":1766441665,"startTime":"0","endTime":"0","summary":"格隆汇12月23日｜今日翰思艾泰-B(3378.HK)、轻松健康(2661.HK)、诺比侃(2635.HK)上市，壁仞科技(6082.HK)、卧安机器人(6600.HK)、英硅智能(3696.HK)、美联股份(2671.HK)、五一视界(6651.HK)、迅策(3317.HK)及林清轩(2657.HK)申购。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223061513a6c2f5df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223061513a6c2f5df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1535","03696","03378","BK1173"],"gpt_icon":0},{"id":"2593278436","title":"翰思艾泰生物(3378)香港公開發售超額認購3074倍 基石投資者認購15.93% 擬於12月...","url":"https://stock-news.laohu8.com/highlight/detail?id=2593278436","media":"新浪财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593278436?lang=zh_tw&edition=fundamental","pubTime":"2025-12-22 23:20","pubTimestamp":1766416827,"startTime":"0","endTime":"0","summary":"本次全球发售共发行18,321,000股H股，其中香港公开发售占10%，即1,832,100股，国际配售占90%，即16,488,900股，超额配售权未获行使。认购情况方面，香港公开发售获得3,074.09倍超额认购，国际配售超额认购5.78倍。由于未触发回拨机制，香港公开发售及国际配售最终股数维持初始比例，分别占总发售股份的10%和90%。基石投资者方面，本次发行共有7家基石投资者参与，合计认购2,917,800股，占全球发售股份总数的15.93%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222232321a46b0acf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251222232321a46b0acf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1173","03378","BK1535"],"gpt_icon":1}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}